LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

Search

Onconova Therapeutics Inc

Avatud

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+406.99% upside

Onconova Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. veebr 2026, 22:36 UTC

Tulu

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. veebr 2026, 22:32 UTC

Tulu

Woodside Energy Fiscal Year Net Profit Falls 24%

23. veebr 2026, 23:58 UTC

Market Talk
Tulu

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. veebr 2026, 23:58 UTC

Market Talk
Tulu

Global Energy Roundup: Market Talk

23. veebr 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. veebr 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Crescent Capital Partners Owns 53% of ClearView Wealth

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. veebr 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. veebr 2026, 23:27 UTC

Tulu

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. veebr 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. veebr 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. veebr 2026, 22:31 UTC

Tulu

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. veebr 2026, 22:24 UTC

Tulu

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Underlying Ebitda A$700.9 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. veebr 2026, 22:20 UTC

Tulu

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Võrdlus sarnastega

Hinnamuutus

Onconova Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

406.99% tõus

12 kuu keskmine prognoos

Keskmine 7.25 USD  406.99%

Kõrge 8 USD

Madal 6.5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Onconova Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat